Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 7/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | SELE | P16581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13472439 | 0.87 | MEN1 (0.39) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL13472438 | 0.71 | KMO (0.39) | KMO | |
| SCHEMBL21738201 | 0.71 | MEN1 (0.42) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1808138 | 0.70 | MEN1 (0.49) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL13472441 | 0.69 | KMO (0.37) | KMO | |
| SCHEMBL2644185 | 0.69 | KMT2A (0.51) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL13322302 | 0.69 | MEN1 (0.51) | MEN1KMT2AKDM4CL3MBTL1CREBBP | |
| SCHEMBL3511939 | 0.69 | KDM4C (0.56) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL18873291 | 0.69 | MEN1 (0.69) | MEN1KMT2AKDM4CCREBBPGCK | |
| SCHEMBL29877431 | 0.69 | MEN1 (0.46) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3231798-B1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-9920048-B2 | Substituted pyrimidines for inhibiting Raf kinase activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3231798-A1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2167489-B1 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9556177-B2 | Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150080568-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | XOMA (US) LLC | 2015-03-19 | — | — | US | disclosed |
| US-8802657-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130065858-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8293752-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293752-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MEN1 2221/4885KMT2A 1963/4885KMO 3678/4885 |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | BRAF, RAF1, ARAF | MEN1 2221/4885KMT2A 1963/4885KMO 3678/4885 |
| US-20130065858-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MEN1 2221/4885KMT2A 1963/4885KMO 3678/4885 |
| US-20150080568-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MEN1 2221/4885KMT2A 1963/4885KMO 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.